Results 31 to 40 of about 7,633 (200)

Effect of MMX® mesalamine coadministration on the pharmacokinetics of amoxicillin, ciprofloxacin XR, metronidazole, and sulfamethoxazole: results from four randomized clinical trials

open access: yesDrug Design, Development and Therapy, 2014
David Pierce,1 Mary Corcoran,2 Patrick Martin,2 Karen Barrett,1 Susi Inglis,1 Peter Preston,2 Thomas N Thompson,3 Sandra K Willsie3 1Shire, Basingstoke, UK; 2Shire, Wayne, PA, USA; 3PRA International, Lenexa, KS, USA Background: MMX® mesalamine is a
Pierce D   +7 more
doaj   +1 more source

Mesalamine-Induced Eosinophilic Pneumonia. [PDF]

open access: yesCureus
Eosinophilic pneumonia encompasses a group of lung disorders characterized by peripheral blood eosinophilia. While its etiology is often idiopathic or infectious, non-infectious causes, including drug-induced reactions, should also be considered. Common culprits of drug-induced eosinophilic pneumonia include daptomycin, phenytoin, and nitrofurantoin ...
Sharma M, Sotelo JE, Schultz S.
europepmc   +3 more sources

Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX® mesalamine

open access: yesClinical Pharmacology: Advances and Applications, 2012
Kavinderjit Nanda, Alan C MossCenter for Inflammatory Bowel Disease, BIDMC/Harvard Medical School, Boston, MA, USAAbstract: Ulcerative colitis (UC) is a chronic inflammatory disease of the colon that typically manifests as diarrhea, abdominal pain, and ...
Nanda K, Moss AC
doaj   +1 more source

Mesalamine-induced myocarditis following diagnosis of Crohn's disease: A case report [PDF]

open access: yesRevista Portuguesa de Cardiologia, 2013
Mesalamine is a common treatment for Crohn's disease, and can be rarely associated with myocarditis through a mechanism of drug hypersensitivity. We present the case of a 19-year-old male who developed chest pain two weeks after beginning mesalamine ...
Carlos Galvão Braga   +7 more
doaj   +2 more sources

Drug-Induced Intersticial Nephritis. Clinical Case

open access: yesActa Medica Lituanica, 2021
5-Aminosalicylic acid (5-ASA) preparations are widely used in the treatment of inflammatory bowel diseases. The most commonly used medicine is mesalamine. Overall, it is a very safe drug with few side effects.
Paulina Tekoriutė   +2 more
doaj   +1 more source

Genetic variants in cellular transport do not affect mesalamine response in ulcerative colitis. [PDF]

open access: yesPLoS ONE, 2018
Mesalamine is commonly used to treat ulcerative colitis (UC). Although mesalamine acts topically, in vitro data suggest that intracellular transport is required for its beneficial effect.
Christopher J Moran   +5 more
doaj   +1 more source

Human immunodeficiency virus infection mimicking very early onset inflammatory bowel disease [PDF]

open access: yesJPGN Rep
Abstract Very early onset inflammatory bowel disease (VEO‐IBD), defined as diagnosis before 6 years of age, is often associated with immune dysregulation and monogenic etiologies; however, infectious mimics may be overlooked in low‐prevalence regions. We report a 4‐year‐old male with poor weight gain, intermittent diarrhea, elevated fecal calprotectin,
Abi Radi Abou Jaoudeh R, Sauer C, Oh T.
europepmc   +2 more sources

Induction of oxidative DNA damage by mesalamine in the presence of copper: A potential mechanism for mesalamine anticancer activity [PDF]

open access: yes, 2011
Mesalamine is the first line pharmacologic intervention for patients with ulcerative colitis, and recent epidemiologic studies have demonstrated a protective association between therapeutic use of the drug and colorectal carcinoma. However, the mechanism
NC DOCKS at The University of North Carolina at Greensboro   +1 more
core   +2 more sources

Mesalamine-Loaded Microsponges as a Potential Strategy for Colon-Specific Drug Delivery [PDF]

open access: yes, 2023
Mesalamine, a key therapeutic agent for inflammatory bowel disease (IBD), often suffers from suboptimal release and therapeutic efficacy due to premature drug release in the upper gastrointestinal tract.
Vaishnavi Sahu, Arun Patel, Shailendra Patel
core   +1 more source

Efficacy and safety of two pH-dependent-release mesalamine doses in moderately active ulcerative colitis: a multicenter, randomized, double-blind, parallel-group study [PDF]

open access: yesIntestinal Research, 2016
Background/AimsThe therapeutic effect of mesalamine is considered to be dose-dependent; however, no consensus has been reached regarding the optimal doses for individual patients.
Yasuo Suzuki   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy